Ticagrelor is an allosteric antagonist of P2Y12, acting directly via reversible binding to the P2Y12 receptor, which leads to the non-competitive inhibition of ADP-induced P2Y12 activation and is used for the prevention of thromboembolic events in patients with acute coronary syndromes [2,3,4,5]. The gene discussed is P2RY12; the disease is acute coronary syndrome.